Corbus Pharmaceuticals (CRBP) Price & Analysis

Compare

2,479 Followers

CRBP Stock Chart & Stats

$11.69

-$0.10(-0.79%)

At close: Jan 08 4:00 PM EST

$11.69

-$0.10(-0.79%)

Day’s Range― - ―

52-Week Range$4.64 - $20.56

Previous CloseN/A

Volume39.58K

Average Volume (3M)503.64K

Market Cap

$128.92M

Enterprise Value-$29.96M

Total Cash (Recent Filing)$26.98M

Total Debt (Recent Filing)$2.05M

Price to Earnings (P/E)―

Beta2.20

Next Earnings

Mar 17, 2026

EPS Estimate

-1.31

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.90

Shares Outstanding12,255,225

10 Day Avg. Volume744,820

30 Day Avg. Volume503,638

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)0.90

Price to Sales (P/S)0.00

P/FCF Ratio-3.08

Enterprise Value/Market Cap-0.23

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit1.89

Enterprise Value/Ebitda0.44

Forecast

1Y Price Target

$44.38

Price Target Upside279.64% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessCorbus' CRB-701 is clearly meeting the bar for success in the HNSCC patient population, with a 47.6% ORR at the 3.6 mg/kg dose level among efficacy-evaluable HNSCC patients.

Financial PositionCorbus ended the third quarter with $104.0 million in cash, with an estimated pro forma cash level of about $177.8 million after the recent public offering.

Regulatory ApprovalThe FDA granted Fast Track Designation to CRB-701 in Head and Neck Squamous Cell Carcinoma, marking the second Fast Track designation for this drug.

Bears Say

Historical Drug Approval ChallengesCRB-913 is designed to be more peripherally restricted than the first generation CB1R inverse agonist, rimonabant, which failed to receive US approval due to neuropsychiatric concerns.

Publication ConcernsManagement does not expect full results of CRB-913 to be published.

Corbus Pharmaceuticals News

Corbus Pharmaceuticals price target lowered to $53 from $55 at RBC Capital

RBC Capital analyst Brian Abrahams lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $53 from $55...

8d ago

CRBP

Corbus Pharmaceuticals sees cash runway into 2028

As of September 30, 2025, the Company had $104.0 million of cash, cash equivalents, and investment on hand....

9d ago

CRBP

Corbus Pharmaceuticals reports Q3 EPS ($1.90), consensus ($1.71)

“This has been a productive period for Corbus, led by the presentation of CRB-701 data at ESMO 2025,”...

9d ago

CRBP

Corbus Pharmaceuticals management to meet virtually with B. Riley

Virtual Meeting to be held on November 7 hosted by B. Riley. Published first on TheFly – the...

15d ago

CRBP

Corbus Pharmaceuticals management to meet virtually with B. Riley

Virtual Meeting to be held on November 10 hosted by B. Riley. Published first on TheFly – the...

15d ago

CRBP

Corbus Pharmaceuticals 4.744M share Spot Secondary priced at $13.00

The deal range was $13.00-$14.00. Jefferies and Piper Sandler acted as joint book running managers for the offering....

22d ago

CRBP

Corbus Pharmaceuticals TBA Spot Secondary; price range $13.00-$14.00

Jefferies and Piper Sandler are acting as joint book running managers for the offering. Published first on TheFly...

22d ago

CRBP

Corbus announces common stock and warrants offering, no amount given

Corbus Pharmaceuticals (CRBP) Holdings announced that it plans to offer and sell shares of its common stock or,...

22d ago

CRBP

Corbus Pharmaceuticals price target raised to $39 from $32 at Mizuho

Mizuho raised the firm’s price target on Corbus Pharmaceuticals (CRBP) to $39 from $32 and keeps an Outperform...

23d ago

CRBP

Corbus Pharmaceuticals: Promising Pipeline and Strategic Plans Justify Buy Rating

Corbus Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Oliver McCammon from...

8d ago

CRBP

Corbus Pharmaceuticals Advances Oncology and Obesity Pipeline

Corbus Pharmaceuticals Holdings ( ($CRBP) ) has released its Q3 earnings. Here is a breakdown of the information...

9d ago

CRBP

Corbus Pharmaceuticals: Strong Financials and Promising Clinical Pipeline Drive Buy Rating

William Blair analyst Andy Hsieh has reiterated their bullish stance on CRBP stock, giving a Buy rating on...

9d ago

CRBP

Corbus Pharmaceuticals Completes $75 Million Public Offering

The latest update is out from Corbus Pharmaceuticals ( ($CRBP) ). Corbus Pharmaceuticals reported its third quarter 2025...

9d ago

CRBP

CRBP Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Corbus Pharmaceuticals Holdings (CRBP) is scheduled to report 3rd quarter earnings on 11/11/2025. Regarding Q3 estimates, Wall Street...

13d ago

CRBP

CRBP FAQ

What was Corbus Pharmaceuticals’s price range in the past 12 months?

Corbus Pharmaceuticals lowest stock price was $4.64 and its highest was $20.56 in the past 12 months.

What is Corbus Pharmaceuticals’s market cap?

Corbus Pharmaceuticals’s market cap is $128.92M.

When is Corbus Pharmaceuticals’s upcoming earnings report date?

Corbus Pharmaceuticals’s upcoming earnings report date is Mar 17, 2026 which is in 115 days.

How were Corbus Pharmaceuticals’s earnings last quarter?

Corbus Pharmaceuticals released its earnings results on Nov 12, 2025. The company reported -$1.9 earnings per share for the quarter, missing the consensus estimate of -$1.657 by -$0.243.

Is Corbus Pharmaceuticals overvalued?

According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Corbus Pharmaceuticals pay dividends?

Corbus Pharmaceuticals does not currently pay dividends.

What is Corbus Pharmaceuticals’s EPS estimate?

Corbus Pharmaceuticals’s EPS estimate is -1.31.

How many shares outstanding does Corbus Pharmaceuticals have?

Corbus Pharmaceuticals has 12,255,225 shares outstanding.

What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?

Corbus Pharmaceuticals reported an EPS of -$1.9 in its last earnings report, missing expectations of -$1.657. Following the earnings report the stock price went up 7.39%.

Which hedge fund is a major shareholder of Corbus Pharmaceuticals?

Currently, no hedge funds are holding shares in CRBP

Corbus Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-55.65%

Trailing 12-Months

Asset Growth

-17.70%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a clinical-stage pharmaceutical company specializing in the development and commercialization of novel therapeutics for the treatment of inflammatory and fibrotic diseases. The company's primary focus is on harnessing the potential of the endocannabinoid system to develop drugs that address chronic diseases with significant unmet medical needs. Corbus is engaged in developing a pipeline of innovative drug candidates targeting these conditions, with a particular emphasis on rare inflammatory diseases.

Corbus Pharmaceuticals (CRBP) Earnings & Revenues

Historic Earnings Reports

CRBP Stock 12 Month Forecast

Average Price Target

$44.38

▲(279.64% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","29":"$29","54":"$54","16.5":"$16.5","41.5":"$41.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$53.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$44.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,16.5,29,41.5,54],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.15,15.292307692307693,18.434615384615384,21.576923076923077,24.71923076923077,27.861538461538462,31.003846153846155,34.146153846153844,37.28846153846154,40.43076923076923,43.573076923076925,46.715384615384615,49.857692307692304,{"y":53,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.15,14.62923076923077,17.10846153846154,19.587692307692308,22.06692307692308,24.54615384615385,27.025384615384617,29.504615384615384,31.98384615384616,34.463076923076926,36.94230769230769,39.42153846153847,41.900769230769235,{"y":44.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.15,13.36923076923077,14.588461538461539,15.807692307692307,17.026923076923076,18.246153846153845,19.465384615384615,20.684615384615384,21.903846153846153,23.123076923076923,24.342307692307692,25.56153846153846,26.78076923076923,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.92,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.79,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.03,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.34,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.74,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.15,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >